Evidence map›Paper›PMID 25343005›Full record

ArticleStatistics in biopharmaceutical research2014

Estimation of Drug Effectiveness by Modeling Three Time-dependent Covariates: An Application to Data on Cardioprotective Medications in the Chronic Dialysis Population.

Milind A Phadnis, Theresa I Shireman, James B Wetmore, Sally K Rigler, Xinhua Zhou, John A Spertus, Edward F Ellerbeck, Jonathan D Mahnken

Abstract read
In one paragraph

Article in Statistics in biopharmaceutical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Milind A PhadnisDepartment of Biostatistics, University of Kansas School of Medicine, Kansas City, KS, USA.
Theresa I ShiremanDepartment of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA ; The Landon Center on Aging, University of Kansas School of Medicine, Kansas City, KS, USA.
James B WetmoreDepartment of Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, Kansas City, KS, USA.
Sally K RiglerDepartment of Medicine, University of Kansas School of Medicine, Kansas City, KS, USA ; The Landon Center on Aging, University of Kansas School of Medicine, Kansas City, KS, USA.
Xinhua ZhouDepartment of Biostatistics, University of Kansas School of Medicine, Kansas City, KS, USA.
John A SpertusSaint Luke's Mid America Heart Institute, Kansas City, MO, USA ; University of Missouri-Kansas City, Kansas City, MO, USA.
Edward F EllerbeckDepartment of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA ; Department of Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
Jonathan D MahnkenDepartment of Biostatistics, University of Kansas School of Medicine, Kansas City, KS, USA.

Funding

Are Cardioprotective Medications Effective in ESRD?R01DK080111 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SHIREMAN, THERESA I. · 2008 to 2011
$1.4M
Factors Associated with Warfarin Use in Dialysis Patients w/ Atrial FibrillationK23DK085378 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WETMORE, JAMES BACON · 2010 to 2014
$861k
NIDDK NIH HHS K23 DK085378NIDDK NIH HHS R01 DK080111
6 · The paper itself

Abstract

In a population of chronic dialysis patients with an extensive burden of cardiovascular disease, estimation of the effectiveness of cardioprotective medication in literature is based on calculation of a hazard ratio comparing hazard of mortality for two groups (with or without drug exposure) measured at a single point in time or through the cumulative metric of proportion of days covered (PDC) on medication. Though both approaches can be modeled in a time-dependent manner using a Cox regression model, we propose a more complete time-dependent metric for evaluating cardioprotective medication efficacy. We consider that drug effectiveness is potentially the result of interactions between three time-dependent covariate measures, current drug usage status (ON versus OFF), proportion of cumulative exposure to drug at a given point in time, and the patient's switching behavior between taking and not taking the medication. We show that modeling of all three of these time-dependent measures illustrates more clearly how varying patterns of drug exposure affect drug effectiveness, which could remain obscured when modeled by the more standard single time-dependent covariate approaches. We propose that understanding the nature and directionality of these interactions will help the biopharmaceutical industry in better estimating drug efficacy.

Indexed as

anti-hypertensive drugsdrug interactionsMarkov modelmedication patternsstate transition model

Identifiers

PMID25343005
PMCPMC4203430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.